ConductScience.org, home
Papers
API referenceFor AI assistants

Paper · 41310273

Towards biomarker-driven therapies for urothelial carcinoma.

Coca Membribes S and 2 others. Nat Rev Clin Oncol, 2026. Cited by 13 papers, by iCite.

11 sourcespapers-2026-11-12-0.1.0

Download JSON
Cite this record

ConductScience Library. Towards biomarker-driven therapies for urothelial carcinoma. Papers, record 41310273. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/41310273

On this page

Paper

PubMed's record of the paper, with iCite's citation figures. No abstract is shown.

Title
Towards biomarker-driven therapies for urothelial carcinoma.
PubMed
Journal
Nat Rev Clin Oncol
PubMed
Year
2026
PubMed
Publication types
Journal Article, Review
PubMed
Citations, by iCite
13
iCite
Relative citation ratio, by iCite
6.75, provisional
iCite
Revised in PubMed
2026-11-05
PubMed

Authors3

The authors in the order PubMed's record lists them, with the ORCID iDs it states.

OrderAuthorForenameKindORCID iD
1Coca Membribes SSarahttps://orcid.org/0000-0001-9769-5766
2Szabados BBernadetthttps://orcid.org/0000-0002-8786-0032
3Powles TThomas

Source PubMed

Topics10

NLM's MeSH indexing of the paper, its major topics first.

MeSH termMajor
Biomarkers, TumorMajor topic
Carcinoma, Transitional CellMajor topic
Urinary Bladder NeoplasmsMajor topic
Urologic NeoplasmsMajor topic
Humans
Immune Checkpoint Inhibitors
Molecular Targeted Therapy
Prognosis
Receptor, Fibroblast Growth Factor, Type 3
B7-H1 Antigen

Source PubMed

Grants0

Each grant PubMed's record writes, matched to the NIH project NIH's grant and paper links name for this paper, and each of those links the record does not write.

None in this release.

Trials0

The trials whose ClinicalTrials.gov record lists the paper, and the trial numbers the paper's PubMed record names.

None in this release.

Comments and corrections0

PubMed's comments and corrections, NLM's own indexing: retractions first, then expressions of concern, errata and updates, and comments last.

None in this release.

References120

The papers the reference list in PubMed's record names, those in our copy of PubMed, in the list's order.

OrderPMIDTitleJournalYearIn PapersSource
137,820,582The cancer-immunity cycle: Indication, genotype, and immunotype.Immunity2023https://conductscience.org/library/papers/37820582PubMed
236,462,464Pan-tumor landscape of fibroblast growth factor receptor 1-4 genomic alterations.ESMO Open2022https://conductscience.org/library/papers/36462464PubMed
339,282,910Perioperative Durvalumab with Neoadjuvant Chemotherapy in Operable Bladder Cancer.N Engl J Med2024https://conductscience.org/library/papers/39282910PubMed
429,848,605Efficacy of BGJ398, a Fibroblast Growth Factor Receptor 1-3 Inhibitor, in Patients with Previously Treated Advanced Urothelial Carcinoma with FGFR3 Alterations.Cancer Discov2018https://conductscience.org/library/papers/29848605PubMed
541,124,210Disitamab Vedotin plus Toripalimab in HER2-Expressing Advanced Urothelial Cancer.N Engl J Med2025https://conductscience.org/library/papers/41124210PubMed
629,443,960TGFβ attenuates tumour response to PD-L1 blockade by contributing to exclusion of T cells.Nature2018https://conductscience.org/library/papers/29443960PubMed
734,782,263Infigratinib in Early-Line and Salvage Therapy for FGFR3-Altered Metastatic Urothelial Carcinoma.Clin Genitourin Cancer2022https://conductscience.org/library/papers/34782263PubMed
825,712,293HER2 expression status in diverse cancers: review of results from 37,992 patients.Cancer Metastasis Rev2015https://conductscience.org/library/papers/25712293PubMed
930,343,614Pembrolizumab as Neoadjuvant Therapy Before Radical Cystectomy in Patients With Muscle-Invasive Urothelial Bladder Carcinoma (PURE-01): An Open-Label, Single-Arm, Phase II Study.J Clin Oncol2018https://conductscience.org/library/papers/30343614PubMed
1027,643,540Association of germline variants in the APOBEC3 region with cancer risk and enrichment with APOBEC-signature mutations in tumors.Nat Genet2016https://conductscience.org/library/papers/27643540PubMed

1 to 10 of 120

See all 120 references

Cited by12

The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 13 citations.

PMIDTitleJournalYearIn PapersSource
42,941,789pH-Responsive Erdafitinib Liposomes with FGFR3 Targeting for Intravesical Bladder Cancer Therapy.Int J Mol Sci2026https://conductscience.org/library/papers/42941789PubMed
42,729,159Disease stage-dependent expression of ADC-related biomarkers in urothelial carcinoma.Transl Androl Urol2026https://conductscience.org/library/papers/42729159PubMed
42,723,945Case Report: Targeting EGFR exon 20 insertion and MTAP loss in refractory metastatic upper tract urothelial carcinoma.Front Oncol2026https://conductscience.org/library/papers/42723945PubMed
42,676,452Mechanisms of resistance to antibody-drug conjugates in bladder cancer.Front Pharmacol2026https://conductscience.org/library/papers/42676452PubMed
42,661,024
ctDNA-guided or ctDNA-stratified adjuvant immunotherapy compared with observation or placebo after radical surgery for muscle-invasive urothelial carcinoma: a GRADE-assessed systematic review and meta-analysis.
World J Urol2026https://conductscience.org/library/papers/42661024PubMed
42,651,823Coordinated Expression of ADC Targets ERBB2, TACSTD2, and NECTIN4 in Bladder Cancer: A Multi-Scale Transcriptomic and Proteomic Landscape Analysis.Curr Issues Mol Biol2026https://conductscience.org/library/papers/42651823PubMed
42,588,611Immune Phenotype in Urothelial Carcinoma: From Tumor Biology to Therapeutic Stratification.Cancers (Basel)2026https://conductscience.org/library/papers/42588611PubMed
42,557,383Integrating clinically actionable biomarkers into bladder cancer care - recommendations from the International Bladder Cancer Group.Nat Rev Urol2026https://conductscience.org/library/papers/42557383PubMed
42,436,777Identification of pyroptosis-related molecular subtypes and development of a subtype-derived six-gene prognostic signature for bladder cancer.Transl Androl Urol2026https://conductscience.org/library/papers/42436777PubMed
42,186,741Engineered CRISPR/Cas12a2 Nanoprobe Imaging in Living Cells for Precise Tumor Diagnosis.Small Methods2026https://conductscience.org/library/papers/42186741PubMed

1 to 10 of 12

See all 12 cited by

Genes3

The genes the Gene search release ties to the paper: Swiss-Prot's references first, then PubTator's text mining.

GeneNCBI Gene IDLinked byIn GenesSource
CD27429,126PubTator's text mininghttps://conductscience.org/library/genes/29126NCBI Gene
ERBB22,064PubTator's text mininghttps://conductscience.org/library/genes/2064NCBI Gene
FGFR32,261PubTator's text mininghttps://conductscience.org/library/genes/2261NCBI Gene

Drugs0

The drugs whose trials, in the Pipelines release, list the paper.

None in this release.

Data0

The data bank entries PubMed's record names. Trial numbers are under Trials.

None in this release.

Data dates

The date of each source this release read.

PubMed
2026-11-06
PubMed
iCite
2026-11-05
iCite
PMC's ID file
2026-11-05
PMC's ID file
NIH RePORTER's grant and paper links
2026-11-01
NIH RePORTER's grant and paper links
Trials
2026-11-12
Gene search
2026-11-11
Pipelines
2026-09-18

Sources 11

  • ChEMBL, through Open TargetsCC BY-SA 3.0
  • ClinicalTrials.govNo license stated
  • HGNCCC0
  • iCiteCC BY 4.0
  • NCBI GenePublic domain (US government)
  • NIH RePORTER's grant and paper linksPublic domain
  • Open TargetsCC0 1.0
  • PMC's ID filePublic domain (US government)
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0
Each source's terms
  • ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • ClinicalTrials.govnone stated
  • HGNCCC0: https://www.genenames.org/about/license/
  • iCiteCC BY 4.0
  • NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
  • Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this paper from software.

The record and each of its lists are JSON, twenty rows a page. No key.

GET https://conductscience.org/api/papers/v1/41310273

GET https://conductscience.org/api/papers/v1/41310273/references?page=2

API referenceFor AI assistants